PDMR Notification RSU Vesting

RNS Number : 0232M

PureTech Health PLC

19 May 2022

 

19 May 2022

PureTech Health plc

PDMR Notifications

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 20 December 2019 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP")  vested at 95.8% on 3 February 2022 following satisfaction of performance conditions measured over the three year period to 31 December 2021. In addition, certain RSUs granted to George Farmer, PureTech's Chief Financial Officer, pursuant to its PSP vested in full on 1 January 2022 in accordance with a time-based vesting schedule. 

Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 18 May 2022. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 175 pence, being the average closing price of the Company's shares over the three trading day period immediately preceding the settlement, and the exchange rate used to calculate the cash payment and amount of share settlement was £1:$1.2359.

The Company's total issued ordinary share capital is 288,611,159 shares after the share issuance to the PDMRs.

PDMR Notification

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Daphne Zohar Bharatt Chowrira Eric Elenko Joseph Bolen George Farmer
2	Reason for the notification
a)	Position/status	Daphne Zohar - Chief Executive Officer Bharatt Chowrira - President and Chief Business, Legal and Operating Officer Eric Elenko - Chief Innovation and Strategy Officer Joseph Bolen - Chief Scientific Officer George Farmer - Chief Financial Officer
b)	Initial notification/Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	PureTech Health plc
b)	LEI	213800LVPDNO2Z9T9I39
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of PureTech Health plc ISIN GB00BY2Z0H74
b)	Nature of the transaction	Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.
c)	Price(s) and volume(s)	Recipient Price Amount Daphne Zohar 0.01 GBP 366,882 ordinary shares Bharatt Chowrira 0.01 GBP 69,600 ordinary shares Eric Elenko 0.01 GBP 127,476 ordinary shares Joseph Bolen 0.01 GBP 127,476 ordinary shares George Farmer 0.01 GBP 18,282 ordinary shares
d)	Aggregated information - Aggregated volume - Price	Price Aggregate Volume 0.01 GBP 709,717 ordinary shares
e)	Date of the transaction	18 May 2022
f)	Place of the transaction	London Stock Exchange (XLON)

About PureTech Health 

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.

This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

[e-mail]

 

END

 

 

DSHGPUBWAUPPGBR